Efficacy and Safety of Losartan in Children With Ig A Nephropathy

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: Ministry of Food and Drug Safety, Korea
• Treatments: Losartan

Criteria

Inclusion Criteria:

• Age: 2years or older and younger than 18 years

• Biopsy-proven Ig A Nephropathy

• Estimated GFR ≥ 90mL/min/m^2

• Mean urinary protein-creatinine ratio > 0.3 g/g from three first-morning spot urine collections

Exclusion Criteria:

• hypertension

• under dialysis or organ transplanted

• bilateral renal artery stenosis

• primary hyperaldosteronism

• pregnant